However, fatigue can be a common side effect of Type II diabetes (1-5)
Castrillon F et al
When compared to those taking topiramate, GLP-1 users were: 48% less likely to start valproate 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies 35% less likely to start tricyclic antidepressants 23% less likely to start the class of drugs called gepants However, there was no significant difference between the two groups, and the need to begin taking beta-blockers
No insurance, membership, or hidden fees applyall prices remain flat regardless of dose adjustments
Monitoring hydration, kidney function, and pancreatitis risk is essential with these therapies
Understanding GLP-1 Receptor Agonists GLP-1 medications, clinically known as receptor agonists, replicate this exact natural process